Clinical trial
An Open Label Trial to Investigate Macugen for the Preservation of Visual…
NCT00327470 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00327470 |
|---|---|
| Title | An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD |
| Official title | A 102-Week, Open Label, Multicenter Trial To Investigate The Efficacy Of Macugen For The Preservation Of Visual Function In Subjects With Neovascular Age-Related Macular Degeneration (AMD) And To Assess The Benefit Of Treating Early Choroidal Neovascularization (CNV). |
| Acronym | PERSPECTIVES |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Age Related Macular Degeneration (AMD), Macular Degeneration, Choroidal Neovascularization (CNV) |
| Intervention type | Drug |
| Interventions | Pegaptanib Sodium 0.3 mg |
| Enrollment | 288 |
| Start date | Jul 1, 2006 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | May 18, 2006 |
| Last update posted | Apr 4, 2012 |
| Countries | Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Poland, Portugal and 3 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: